What Are Bispecific Antibodies and Why Do They Matter?

Bispecific antibodies (bsAbs) represent a groundbreaking advancement in immunotherapy, engineered to bind simultaneously to two different antigens or epitopes on target cells. Unlike traditional monoclonal antibodies that target a single antigen, bsAbs offer enhanced therapeutic efficacy by recruiting immune cells to tumors or bridging dual signaling pathways for more precise cancer treatment. In Singapore's thriving biotech ecosystem, research into bsAbs is accelerating, driven by institutions like the Agency for Science, Technology and Research (A*STAR). This positions the nation as a hub for next-generation biologics development.

The structural design of bsAbs is crucial, with formats divided into symmetric (identical arms) and asymmetric (different arms). Symmetric bsAbs, often using linkers like G4S (Gly-Gly-Gly-Gly-Ser) or G4 (Gly-Gly-Gly-Gly), promise simpler manufacturing but raise questions about long-term stability during production, storage, and administration.

A*STAR's Latest Breakthrough: Probing Symmetric bsAb Stability

Researchers at A*STAR's Bioprocessing Technology Institute (BTI) have published a pivotal study in Scientific Reports (February 18, 2026), titled "Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions." Led by Nattha Ingavat and colleagues, the work examines a symmetric bsAb targeting HER2 (human epidermal growth factor receptor 2, overexpressed in breast cancers) and CD3 (on T-cells for immune recruitment).

This HER2/CD3 Sym-bsAb exemplifies symmetric designs where identical heavy and light chains form dual-binding arms connected by flexible linkers. The study addresses a critical gap: while symmetric formats reduce complexity in cell line development and purification, their stability under stress remains underexplored.

Methods: Forced Degradation to Unmask Vulnerabilities

To evaluate stability, the team subjected the Sym-bsAb to forced degradation conditions mimicking manufacturing stresses: thermal (40°C), acidic/low pH, basic/high pH, oxidative, and combinations like high pH with salt. Techniques included size-exclusion chromatography (SEC) for aggregation/fragmentation, intact mass spectrometry for precise clipping sites, and peptide mapping.

Intact mass analysis proved invaluable, revealing mass shifts corresponding to linker cleavages. For instance, sequential loss of G4S repeats (each ~0.3 kDa) pinpointed exact degradation hotspots. This rigorous, multi-analytical approach highlights BTI's expertise in bioprocess analytics.

Key Findings: Linker Clipping and Fragmentation Hotspots

Under prolonged thermal stress (especially with high pH and salt), the Sym-bsAb showed marked fragmentation, unlike robust aggregation resistance. Primary degradation:

• G4S and G4 linker clipping: Sequential removal from vulnerable glycine-serine repeats, compromising arm integrity.
• Interchain disulfide fragmentation: Cleavage at cystinyl residues linking heavy/light chains.
• Asn C-terminal nicks: Deamidation/asparaginase activity at asparagine ends.

High pH + salt accelerated these, suggesting ionic interactions destabilize linkers. Symmetric design's identical arms may amplify uniform stress exposure, unlike asymmetric formats' varied resilience.

Comparing Symmetric vs. Asymmetric bsAbs

BTI's prior work (e.g., 2025 Fab-scFv study) showed asymmetric bsAbs excel in thermal/pH stability. Symmetric formats simplify production but risk linker hotspots. The study recommends linker optimization—shorter/rigid sequences or mutations—to bolster manufacturability without efficacy loss. For HER2/CD3 targeting, this could enhance T-cell redirection for solid tumors.

Photo by Tim Mossholder on Unsplash

Implications for Biomanufacturing and Therapeutics

Fragmentation risks immunogenicity, potency loss, and regulatory hurdles. Insights guide early-stage engineering: screen linkers via predictive models, refine purification (e.g., BTI's mixed-mode chromatography). In Singapore, this aligns with Biopharma 2030 goals, boosting yields for clinical translation.

Real-world impact: Faster, cheaper bsAb production could slash costs from $100M+ per candidate, aiding access in Asia-Pacific cancers like HER2+ breast (prevalent regionally).

Singapore's Biotech Boom: A*STAR at the Forefront

A*STAR BTI leads Singapore's antibody R&D, with facilities for upstream/downstream optimization. Recent highlights include Fab-scFv stability under extremes and impurity polishing for 97% purity. Collaborations with NUS/NTU fuel talent pipeline; BTI trains PhDs/postdocs in bioprocessing.

Singapore's $4B biopharma investments (2025) position it for bsAb trials. Linker stability advances support EDB's push for 20+ manufacturing suites by 2030.

Explore research jobs at A*STAR or universities.

Global Trends and Singapore's Edge

Globally, 26+ bsAbs approved by 2026 (e.g., Ziihera Fab-scFv, FDA 2024). Challenges: Heterogeneity, stability. Singapore excels via A*STAR's analytics; 2025 perfusion culture doubled symmetric bsAb yields.

Stakeholders praise: Pharma execs note cost savings; regulators value predictive stability data. Case: Blinatumomab (asymmetric) success inspires symmetric tweaks.

Challenges and Solutions in bsAb Engineering

• Linker design: Rigid alternatives (e.g., knob-hole) reduce flexibility-induced clips.
• Analytics: Intact MS mandatory for early detection.
• Formulation: Low-salt buffers mitigate ionic stress.

BTI's roadmap: AI-driven linker prediction, integrating with cell-free expression.

Future Outlook: Revolutionizing Cancer Therapy

Symmetric bsAbs could dominate if stability hurdles cleared—simpler scale-up for CAR-T alternatives. Singapore eyes trials by 2028; A*STAR collaborations with Takeda/Chugai accelerate.

Actionable: Biotech firms should audit linkers pre-clinic. Students, pursue bioprocessing via postdoc roles.

Photo by Ingmar on Unsplash

Careers in Singapore's Antibody Research

Singapore demands experts in bsAb analytics. A*STAR/NUS offer roles in stability, purification. Craft your CV for biopharma. With 10K jobs by 2030, now's time—check higher-ed-jobs.

Conclusion: Stability as Key to bsAb Success

A*STAR's study illuminates linker pitfalls in symmetric bsAbs, paving manufacturable paths. Singapore leads, blending research prowess with industry. Stay ahead: Rate professors on Rate My Professor, seek university jobs, or explore career advice.